Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences (Q36364965)

13 August 2017

1 reference

title

Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences (English)

1 reference

13 August 2017

1 reference

Vaziri ND

1

1 reference

13 August 2017

1 February 2006

1 reference

American Journal of Physiology - Renal Physiology

13 August 2017

1 reference

13 August 2017

290

1 reference

13 August 2017

F262-72

1 reference

13 August 2017

2

1 reference

Identification of scavenger receptor SR-BI as a high density lipoprotein receptor

13 August 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Lipoprotein metabolism and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Lipid abnormalities in uremia, dialysis, and transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Plasma triglyceride secretion and metabolism in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Plasma alpha 2 macroglobulin is increased in nephrotic patients as a result of increased synthesis alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Cellular cholesterol efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Adipose Tissue Lipoprotein Lipase in Chronic Hemodialysis: Role in Plasma Triglyceride Metabolism*

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

The effects of chronic uremia and dexamethasone on triglyceride kinetics in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

LRP: a multifunctional scavenger and signaling receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Hyperlipoproteinemia in experimental chronic renal insufficiency in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Outcome research, nutrition, and reverse epidemiology in maintenance dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Upregulation of lipogenic enzymes genes expression in white adipose tissue of rats with chronic renal failure is associated with higher level of sterol regulatory element binding protein-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Glucose and insulin metabolism in uremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Why is chronic kidney disease the "spoiler" for cardiovascular outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

HDL and the inflammatory response induced by LDL-derived oxidized phospholipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Tangier disease and ABCA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Post-transcriptional regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol 7 alpha-hydroxylase in rats with subtotal nephrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Noncholesterol-Lowering Effects of Statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Inflammation in end-stage renal disease: sources, consequences, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Molecular mechanisms of lipid disorders in nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Oxidative stress in uremia: nature, mechanisms, and potential consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Downregulation of hepatic acyl-CoA:diglycerol acyltransferase in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Up-regulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Down-regulation of hepatic LDL receptor expression in experimental nephrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Down-regulation of VLDL receptor expression in chronic experimental renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Triglyceride turnover in severe chronic non-nephrotic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Lipoprotein lipase controls fatty acid entry into adipose tissue, but fat mass is preserved by endogenous synthesis in mice deficient in adipose tissue lipoprotein lipase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00099.2005

10.1152/AJPRENAL.00099.2005

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16403839